About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Cardiovascular Diseases group is a translational research group within the Cardiology Department of Vall d’Hebron Hospital that performs laboratory, clinical and epidemiological research. In the CIBERCV network we are within the topic of descriptor 2 “Arterial disease, thrombosis and myocardial ischemia-reperfusion injury”. Our contributions in these topics address the following lines:
In the CIBERESP network, our group is interested in the study of effectiveness/cost-effectiveness of cardiovascular interventions, health outcome research and methods in clinical research. The group has 19 principal investigators, 32 active projects and clinical trial and has been done 142 publications in 2020.
PMID: 35039531 Journal: Nature Reviews Disease Primers Year: 2022 Reference: Nat Rev Dis Primers. 2022 Jan 17;8(1):3. doi: 10.1038/s41572-022-00338-w. Impact factor: 52.329 Publication type: Letter or abstract Authors: Pyeritz, Reed E, Milewicz, Dianna M, Braverman, Alan C, De Backer, Julie, Morris, Shaine A, Boileau, Catherine, Maumenee, Irene H, Jondeau, Guillaume, Evangelista, Arturo et al. DOI: 10.1038/s41572-022-00338-w
PMID: 35035939 Journal: Clinical Kidney Journal Year: 2022 Reference: Clin Kidney J. 2021 Sep 3;15(1):79-94. doi: 10.1093/ckj/sfab161. eCollection 2022 Jan. Impact factor: 4.452 Publication type: Paper in international publication Authors: Soler, Maria Jose, Ribera, Aida, Marsal, Josep R, Mendez, Ana Belen, Andres, Mireia, Azancot, Maria Antonia, Oristrell, Gerard, Mendez-Boo, Leonardo, Cohen, Jordana, Barrabes, Jose A et al. DOI: 10.1093/ckj/sfab161
PMID: 34826497 Journal: INTERNATIONAL JOURNAL OF CARDIOLOGY Year: 2022 Reference: Int J Cardiol. 2022 Feb 15;349:150-154. doi: 10.1016/j.ijcard.2021.11.050. Epub 2021 Nov 23. Impact factor: 4.164 Publication type: Paper in international publication Authors: de Dios, Elena, Merenciano-Gonzalez, Hector, Gabaldon-Perez, Ana, Canoves, Joaquim, Racugno, Paolo, Bonanad, Clara, Minana, Gema, Nunez, Julio, Moratal, David, Chorro, Francisco J et al. DOI: 10.1016/j.ijcard.2021.11.050
PMID: 34688853 Journal: CANADIAN JOURNAL OF CARDIOLOGY Year: 2022 Reference: Can J Cardiol. 2022 Jan;38(1):102-112. doi: 10.1016/j.cjca.2021.10.004. Epub 2021 Oct 21. Impact factor: 5.352 Publication type: Paper in international publication Authors: Alkhodair, Abdullah, Sinning, Jan Malte, Cheema, Asim N, Nombela-Franco, Luis, Chamandi, Chekrallah, Campelo-Parada, Francisco, Munoz-Garcia, Erika, Herrmann, Howard C, Testa, Luca, Won-Keun, Kim et al. DOI: 10.1016/j.cjca.2021.10.004
PMID: 33326869 Journal: HEART RHYTHM Year: 2021 Reference: Heart Rhythm. 2021 Apr;18(4):597-604. doi: 10.1016/j.hrthm.2020.12.009. Epub 2020 Dec 14. Impact factor: 6.343 Publication type: Paper in international publication Authors: Francisco-Pascual, Jaume, Rodenas, Eduard, Rivas-Gandara, Nuria, Belahnech, Yassin, San Emeterio, Aleix Olivella, Perez-Rodon, Jordi, Benito, Begona, Santos-Ortega, Alba, Moya-Mitjans, Angel, Casas, Guillem et al. DOI: 10.1016/j.hrthm.2020.12.009
PMID: 33792661 Journal: EUROPACE Year: 2021 Reference: Europace. 2021 Jul 18;23(7):1072-1083. doi: 10.1093/europace/euaa401. Impact factor: 5.214 Publication type: Paper in international publication Authors: Guaricci, Andrea Igoren, Masci, Pier Giorgio, Muscogiuri, Giuseppe, Guglielmo, Marco, Baggiano, Andrea, Fusini, Laura, Lorenzoni, Valentina, Martini, Chiara, Andreini, Daniele, Pavon, Anna Giulia et al. DOI: 10.1093/europace/euaa401
PMID: 33778874 Journal: EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY Year: 2021 Reference: Eur J Cardiothorac Surg. 2021 Sep 11;60(3):524-525. doi: 10.1093/ejcts/ezab157. Impact factor: 4.191 Publication type: Editorail in international publication Authors: Pijuan-Domenech, Antonia et al. DOI: 10.1093/ejcts/ezab157
PMID: 33757510 Journal: Cardiovascular Diabetology Year: 2021 Reference: Cardiovasc Diabetol. 2021 Mar 23;20(1):69. doi: 10.1186/s12933-021-01261-2. Impact factor: 9.951 Publication type: Paper in international publication Authors: Andres-Cordon, Juan F, Trillo, Ramiro, Briales, Juan Alonso, Amat-Santos, Ignacio, Romaguera, Rafael, Diaz, Jose-Francisco, Vaquerizo, Beatriz, Ojeda, Soledad, Cruz-Gonzalez, Ignacio, Morena-Salas, Daniel et al. DOI: 10.1186/s12933-021-01261-2
The consensus document is the result of multidisciplinary work that takes into account the risks associated with all stages of women's lives and the differences compared to men.
The study, which involved Vall d'Hebron, developed an action plan to efficiently allocate resources to patients most at risk of suffering this complication.
In light of this evidence, hospitals such as Vall d'Hebron have already started to include warnings about environmental pollution in their hospital discharge plans after a myocardial infarction.
